REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

04/05/2020 18:05

RNS Number : 8809L
  
GlaxoSmithKline PLC
  
04 May 2020
  
 

GlaxoSmithKline plc (the 'Company')
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Sir Jonathan Symonds




b)


Position/status


Non-Executive Chairman
 




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.93


2,584.170


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr Vindi Banga




b)


Position/status


Senior Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.93


646.043


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr Vivienne Cox




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.93


461.459


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms Lynn Elsenhans




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$42.41


717.329


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr Laurie Glimcher




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$42.41


1,176.571


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr Jesse Goodman




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$42.41


370.051


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms Judy Lewent




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$42.41


389.027


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr Urs Rohner




b)


Position/status


Independent Non-Executive Director




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.93


609.126


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction)




Aggregated volume Price


 




e)


Date of the transaction


2020-04-29




f)


Place of the transaction
 


N/A




 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHQZLFBBELEBBD